相关实验视频

Updated: Sep 14, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

对心脏的纳米攻击:氧化纳米颗粒心脏毒性的分子通路

Oksana Gerzen¹, Salavat Nabiev¹, Alyona Tzybina¹

¹Institute of Immunology and Physiology of the Ural Branch of the Russian Academy of Sciences, Ekaterinburg, Russia.

Toxicology letters

|July 23, 2025

概括

纳米粒子 (Pb_NP) 和可溶性暴露对心脏功能产生负面影响,通过降低肌动力学和改变肌重链 (MHC) 比率. Pb_NP暴露独特地减少了心室MLC 2酸化,表明毒性更高.

科学领域:

心血管毒理学心血管毒理学
纳米医学是一种纳米医学.
分子心脏病学分子心脏病学

背景情况:

暴露是心血管疾病的已知危险因素.
纳米颗粒 (Pb_NP) 影响心脏功能的特定分子机制,特别是在不同的心脏腔室中,仍然不完全理解.
将Pb_NP效应与可溶性形式进行比较对于风险评估至关重要.

研究的目的:

为了研究Pb_NP暴露在不同老鼠心室中的肌肉功能上的分子机制.
为了比较Pb_NP与其可溶性对应物 (Pb(CH₃COO) 的作用).
为了阐明心脏蛋白动力学和酸化的室内特异性变化.

主要方法:

雄性大鼠被暴露在PbO纳米颗粒或酸溶液中六周.
实验室内运动性试验被用来分析肌动力学,行动素滑动速度和合作性.
通过凝电泳测定了髓重链 (MHC) 和轻链 (MLC) 异形含量以及MLC 2酸化.

主要成果:

无论是Pb_NP还是溶性,在所有分析的心室 (心房,右心室和左心室) 中都降低了髓动力学.
在两个暴露组中,心室MHC比率向β-MHC转移,表明收缩性发生了变化.
Pb_NP暴露独特地减少了心室MLC 2酸化,而心房MLC 2酸化则被两种形式的减少.

结论:

暴露在Pb_NP暴露中表现出与可溶性相比相当或更大的心脏毒性,即使在较低的剂量下也是如此.
常见的机制包括减少的髓动力学和改变的MHC配置文件.
减少腹腔MLC 2酸化是Pb_NP心脏毒性的特定分子特征,突出显示了纳米粒子形式在毒理学结果中的重要性.

关键词:

动氨酸-肌氨酸相互作用心脏有毒性 - 心脏有毒性领导领导领导领导领导骨髓素 (Myosin) 是一种可靠的蛋白质.纳米颗粒纳米颗粒

更多相关视频

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

Using Immunofluorescence to Detect PM2.5-induced DNA Damage in Zebrafish Embryo Hearts

Using Immunofluorescence to Detect PM2.5-induced DNA Damage in Zebrafish Embryo Hearts

Published on: February 15, 2021

相关概念视频

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Pathophysiology of Cardiac Performance

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...

Mechanism of Cardiac Arrhythmias

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...